1. Scrip

As Digital Channels Grow In Importance, AZ, Lilly, GSK Seen As Key Engagers

 
• By Anju Ghangurde

Digital physician engagement channels appear to be closing in on the traditional face-to-face approach, with China surging ahead on the digital path. The US and China appear more or less in sync when it comes to self-directed web-detailing, while AstraZeneca, Lilly and GSK lead the charts in terms of digital engagement as perceived by healthcare professionals, a new survey shows.

Digital Health
Digital engagement is increasingly favored by HCPs

It’s probably time to consider upping your firm’s digital ante or at least tweaking it to a more rational digital versus traditional channel mix to engage with healthcare professionals (HCPs), if a 2017 survey by the healthcare solutions provider Indegene is anything to go by.

The survey suggests a narrowing preference gap between the traditional face-to-face channels and digital ones to 12% implying the growing...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Pipeline Watch: Ten Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Merck & Co’s Verona acquisition; venture funding plummets in Q2; how Teva is expanding innovation; Apogee’s Phase II eczema win; and a look at India’s wave of licensing.

Capricor Gets Complete Response For DMD Cell Therapy

 
• By Joseph Haas

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.